Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-15
2009-12-08
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S706000
Reexamination Certificate
active
07629382
ABSTRACT:
A novel neuroprotective agent is disclosed for the treatment and prevention of neurodegenerative disorders which is based on the administration of an effective amount of a tellurium compound which has a specific ability to induce the differentiation and interfere with apoptotic cell death pathways of neuronal PC-12 cells.
REFERENCES:
patent: 3369550 (1968-02-01), Armao
patent: 4752614 (1988-06-01), Albeck et al.
patent: 4761490 (1988-08-01), Albeck et al.
patent: 4929739 (1990-05-01), Sredni et al.
patent: 4962207 (1990-10-01), Albeck et al.
patent: 5093135 (1992-03-01), Albeck et al.
patent: 5102908 (1992-04-01), Albeck et al.
patent: 5262149 (1993-11-01), Sredni et al.
patent: 5271925 (1993-12-01), Sredni et al.
patent: 5576347 (1996-11-01), Sredni et al.
patent: 5654328 (1997-08-01), Sredni et al.
patent: 6428534 (2002-08-01), Joye et al.
patent: 6472381 (2002-10-01), Albeck et al.
patent: 6552089 (2003-04-01), Sredni et al.
patent: 6747008 (2004-06-01), Rodgers et al.
patent: 2003/0148970 (2003-08-01), Besterman et al.
patent: 2008/0260770 (2008-10-01), Sredni et al.
patent: 4007473 (1991-09-01), None
patent: 0583026 (1994-02-01), None
patent: 583026 (1997-04-01), None
patent: 1427415 (1976-03-01), None
patent: WO 96/18392 (1996-06-01), None
patent: WO 96/18401 (1996-06-01), None
patent: WO 96/06618 (1996-07-01), None
patent: WO 01/98325 (2001-12-01), None
patent: WO 03/044038 (2003-05-01), None
patent: WO 2005/060341 (2005-07-01), None
patent: WO 2006/030437 (2006-03-01), None
patent: WO 2006/030438 (2006-03-01), None
patent: WO 2006/030439 (2006-03-01), None
patent: WO 2006/030440 (2006-03-01), None
Delagarza, VW et al. Pharmacologic Treatment of Alzheimer's Disease: An Update. Am Fam Physician 2003; 68: 1365-72.
Shults CW. Treatments of Parkinson Disease. Arch Neurol. 2003; 60: 1680-1684.
Boettner, B et al. The role of Rho GTPases in disease development. Gene 286 (2002) 155-174.
Black et al. “Activation of Interleukin—1β by a Co-Induced Protease”, FEBS Letters, 247(2): 386-390, 1989.
Hara et al. “Inhibition of Interleukin 1β Converting Enzyme Family Proteases Reduces Ischemic and Excitotoxic Neuronal Damage”, PNAS 94: 2007-2012, 1997.
Hardy “The Secret Life of the Hair Follicle”, Trends in Genetics, 8(2): 41-78, 1992.
Examination Report Dated Oct. 29, 2008 From the Government of India, Patent Office Re.: Application No. 2606/CHENP/2006.
Office Action Dated Jan. 26, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/663,031.
Dumont “The Interleukin-1 Families of Cytokines and Receptors: Therapeutic Potential for Immunomodulation and the Treatment of Inflammatory Disorders”, Expert Opinion in Therapeutic Patents, 16(7): 879-912, 2006.
Iupac “Acyl Groups”, Iupac Gold Book, 2 P., Nov. 27, 2007. http://goldbook.iupac.org/A00123.html.
Merck “Human Immunodeficiency Virus (HIV) Infection”, Merck Manual Home Edition for Patients and Caregivers, 10 P., May 19, 2008. http://merck.com/mmhe/sec17/ch199/ch199a.html.
Communication Pursuant to Rules 109 and 110 EPC Dated Nov. 20, 2006 From the European Patent Office Re.: Application No. 04801399.9.
International Preliminary Report on Patentability Dated Apr. 26, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000991.
International Preliminary Report on Patentability Dated Sep. 28, 2006 From the International Bureau of WIPO Re.: Application No. PCT/IB2004/004163.
International Preliminary Report on Patentability Dated Mar. 29, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/000989.
International Preliminary Report on Patentability Dated Mar. 29, 2007 From the International Bureau of WIPO Re.: application No. PCT/IL2005/000990.
International Preliminary Report on Patentability Dated Mar. 29, 2007 From the International Bureau of WIPO Re.: Application No. PCT/Il2005/000992.
Official Action Datcd May 14, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/663,032.
Official Action Dated Aug. 26, 2008 From the Canadian Intellectual Property Office Re.: Application No. 2,550,459.
Official Action Dated Oct. 27, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/663,032.
Official Action Dated May 14, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/663,032.
Gross et al. “Tellurium Dioxide Suspension in the Treatment of Seborrhea Capitis”, A.M.A. Archives of Dermatology, 78(1): 92-94, 1958.
Jimenez et al. “Interleukin 1 Protects From Cytosine Arabinoside-Induced Alopecia in the Rat Model”, esearch Communications, The FASEB Journal, 5: 2456-2458, 1991.
Kalechman et al. “Anti-IL-10 Therapeutic Strategy Using the Immunomodulator AS101 in Protecting Mice From Sepsis-Induced Death: Dependence on Timing of Immunomodulating Intervention”, The Journal of Immunology, 169(1): 384-392, 2002.
Kalechman et al. “Inhibition of Interleukin-10 by the Immunomodulator AS101 Reduces Mesangial Cell Proliferation in Experimental Mesangioproliferative Glomerulonephritis”, The Journal of Biological Chemistry, 279(23): 24724-24732, 2004.
Makarovsky et al. “Tellurium Compound AS101 Induces PC12 Differentiation and Rescue the Neurons From Apoptotic Death”, Annals of the New York Academy of Sciences, 1010: 659-666, 2003.
Shohat et al. “In Vitro Cytokine Profile in Childhood Alopecia Areata and the Immunomodulatory Effects of AS-101”, Clinical and Experimental Dematology, 30(4): 432-434, 2005.
Siderowf et al. “Update on Parkinson Disease”, Annals of Internal Medicine, 138(8): 651-658, 2003.
Sishi et al. “Defective Production of Interleukin-2 (IL-2) in Patients with Alopecia Areata”, Chemical Abstracts, 108: 519, 1988, Abstract.
Sredni et al. “Hair Growth Induction by the Tellurium lmmunomodulator AS101: Association With Delayed Terminal Differentiation of follicular Keratinocytes and Ras-Dependent Up-Regulation of KGF Expression”, The FASEB Journal, 18(2): 400-402, 2004.
Sredni et al. “The Protective Role of the Immunomodulator AS101 Against Chemotherapy-Induced Alopecia Studies on Human and Animal Models”, International Journal of Cancer, 65(1): 97-103, 1996.
International Preliminary Report on Patentability Dated Mar. 29, 2007 From the International Bureau of WIPO Re.: Application No. PCT/IL2005/ 000992.
IPRP (OA 18 Jul. 08).
Official Action Dated Jan. 26, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/663,031.
Office Action Dated Jun. 5, 2008 From the Israeli Patent Office Re.: Application No. 176333.
Kalechman et al. “Up-Regulation by Ammonium Trichloro(Dioxoethylene-0,0′) Tellurate (AS101) of Fas/Apo-1 Expression on B16 Melanoma Cells: Implications for the Antitumor Effects of AS101”, The Journal of Immunology, 161: 3536-3542, 1998.
Sredni et al. “Bone Marrow-Sparing and Prevention of Alopecia by AS101 in Non-Small-Cell Lung Cancer Patients Treated With Carboplatin and Etoside”, Journal of Clinical Oncology, 13(9): 2342-2353, 1995.
Wieslander et al. “Antioxidative Properties of Organotellurium Compounds in Cell Systems”, Biochemical Pharmacology, 55: 573-584, 1998.
Albeck Michael
Sredni Benjamin
BioMAS Ltd.
Claytor Renee
Padmanabhan Sreeni
LandOfFree
Use of tellurium containing compounds as nerve protecting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tellurium containing compounds as nerve protecting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tellurium containing compounds as nerve protecting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4117760